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AMPK exerts an insulin-sensitizing effect on cardiac glucose
uptake by multiple molecular mechanisms including cytoskeleton
reorganization
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Beauloye (1), Sandrine Horman (1), Luc Bertrand (1)
(1) Université catholique de Louvain, Bruxelles, Belgique – (2) Inserm
UMR S1087, University of Nantes et CHU Nantes, l’Institut du Thorax,
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Background: Insulin-resistant cardiomyocytes are characterized by a
decreased ability of insulin to stimulate glucose uptake. We have previously
shown that the activation of AMPK by metformin or phenformin restores
insulin-sensitivity in insulin-resistant cardiomyocytes. The aim of our present
work is to understand by which molecular mechanisms AMPK exerts its
insulin sensitizing effect. In this study we focused on the mTOR/p70S6K
pathway and on cytoskeleton reorganization. mTOR/p70S6K, which is known
to be inhibited by AMPK, is able to reduce insulin signaling via a negative
feedback loop involving serine phosphorylation of IRS-1. On the other hand,
cytoskeleton reorganization, which is a known target of AMPK, is responsible
for the translocation of the glucose transporter GLUT4 to the plasma mem-
brane.
Methods: Adult rat cardiomyocytes were primary cultured and treated
with different agents including insulin, AMPK activator (phenformin), mTOR
inhibitor rapamycin and/or actin cytoskeleton inhibitor latrunculin B. Glucose
uptake was assessed by detritiation of 2-3H-glucose.
Results: First, we tested if rapamycin was able to mimic AMPK activators.
Similarly to phenformin, rapamycin increased the insulin-dependent phosphor-
ylation of Akt involved in the regulation of glucose uptake. Despite the ability
of rapamycin to induce this Akt over-phosphorylation, rapamycin was not able
to restore the insulin-dependent stimulation of glucose uptake like phenformin
did. On the other hand, latrunculin B abolished the insulin-sensitizing action
of phenformin on glucose uptake, in insulin-sensitive as well as in insulin-
resistant cells.
Conclusions: actin cytoskeleton reorganization but not mTOR/p70S6K, is
involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake.
The role played by Small G proteins, known to be involved in the regulation
of actin cytoskeleton is under investigation.
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A role for focal adhesion kinase in the stimulation of glucose transport
in cardiomyocytes
Christophe Montessuit
Université de Genève, FRM Cardiologie, Genève, Suisse
Background: Stimulation of glucose transport in response to insulin or
metabolic stress is an important determinant of cardiomyocytes function and
survival, particularly during ischemia-reperfusion episodes. Stimulation of
glucose transport is markedly impaired in cardiomyocytes exposed to free
fatty acids (FA), despite relative preservation of insulin- or metabolic stress
signaling.
Aim: To determine whether Focal Adhesion Kinase (FAK) activity is
required for stimulation of glucose transport in cardiomyocytes, and whether
FAK downregulation participates in FA-induced impairment of glucose trans-
port stimulation.
Methods: Glucose transport, measured in isolated cardiomyocytes, was
acutely stimulated either by insulin treatment, or by metabolic inhibition with
oligomycin resulting in AMP-activated kinase (AMPK) activation. FAK
activity was inhibited pharmacologically by preincubation with PF-573,228
(PF). FAK activity was assessed from its autophosphorylation on residue
Y397, and from the phosphorylation of paxillin on Y118.
Results: Y397 FAK phosphorylation was reduced in cardiomyocytes
chronically exposed to FA. Preincubation with PF prior to determination of
glucose transport resulted in a significant reduction of oligomycin-stimulated
glucose transport, with a modest reduction in insulin-stimulated glucose trans-
port. Insulin and AMPK signaling was unaffected by PF preincubation.
Intriguingly metabolic stress provoked Y397 FAK dephosphorylation and
deactivation, as evidenced by a concomitant reduction in Y118 paxillin phos-
phorylation.
Conclusions: stimulation of glucose transport by insulin or metabolic
stress in cardiomyocytes requires FAK activity prior to stimulation; FAK
activity is however acutely reduced during metabolic stress. The chronic
reduction of FAK activity in cardiomyocytes exposed to FFA partially
explains the loss of glucose transport responsiveness to insulin or metabolic
inhibition.
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AKT-mediated cardioprotective effects of aldosterone in type 2 diabe-
tic mice
Loubina Fazal, Feriel Azibani, Guillaume Coutance, Nicolas Bihry,
Evelyne Polidano, Régine Merval, Nicolas Vodovar, Jean-Marie Launay,
Claude Delcayre, Jane-Lise Samuel
Inserm U 942, GHU Lariboisière-APHP, Paris, France
Purpose: Studies have shown that aldosterone would have angiogenic
effects, and therefore would be beneficial in the context of cardiovascular dis-
eases. We thus investigated the potential involvement of aldosterone in trig-
gering a cardiac angiogenic response in the context of type-2 diabetes, and the
molecular pathways involved.
Procedure: 3 week-old male mice, overexpressing aldosterone-synthase
(AS), and their controls littermates (WT) were fed with a standard or high fat,
high sucrose (HFHS) diet. After 6 months of diet, mice were sacrificed and
cardiac samples were assayed by RT-PCR, immuno-blotting and -histology.
Findings: HFHS-diet induced type-2 diabetes (D) in WT and AS mice.
VEGFa mRNAs were decreased in WT-D (–43%, P<0.05 vs. WT) while
increased in AS-D mice (+236%, P<0.01 vs. WT-D). In WT-D hearts, the pro-
apoptotic p38-MAPK was activated (P<0.05 vs. WT and AS-D) whereas Akt
activity decreased. The AS-mice, that exhibited a cardiac upregulation of
IGF1-R, showed an increase in Akt phosphorylation when diabetic (P<0.05
vs. WT and AS-D). Contrary to WT-D, AS-D hearts did not express inflam-
matory markers and exhibited a normal capillary density (P<0.05 vs. WT-D)
Conclusions: To our knowledge, this is the first study providing new
insights into the mechanisms whereby aldosterone prevents diabetes-induced
cardiac disorders.
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Deranged myofilament O’GlcNacylation and function in myocardium
of obese patients
Nicolas Debry (1), Xavier Maréchal (2), David Montaigne (2)
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siologie, Lille, France
The obesity-related cardiomyopathy is a poorly explained disease. There is
no data available on myofilaments sensitivity to calcium and post-transla-
tionnal modification or isoform shifts of sarcomeric proteins that could be
involved in the contractile impairment. We conducted a study on obese and
non obese human atrial trabeculae of the right atrium collected in the surgery
room during cardiopulmonary bypass. We studied the contractile force of the
trabeculae, the sensitivity of the myofilaments to Ca2+. Western blots were
performed in order to explore the post-translationnal modification of sarco-
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meric proteins including phosphorylation and O’GlcNacylation. Finally we
explored the acute ex vivo effect of the modulation of O’GlcNac on the myo-
filament sensitivity to calcium. There was a significant contractile dysfunction
in obese subjects compared to normal subjects, in both the force (p=0.01) and
myofilaments sensitivity to calcium concerning the Fmax (p=0.03). No change
in the expression of genes encoding sarcomeric proteins or enzymes involved
in post-translationnal modification; nor phosphorylation modification of sarco-
meric proteins like cMLC2 or cTnI in obese patients was observed. Con-
versely, we showed in obese patients a decreasing O’GlcNacylation of
proteins of 25 kDa (p=0.007) and 130 kDa (p=0.03) which include the sarco-
meric proteins MLC2 and Troponin I. Finally, we pointed out that alteration
of the O’GlcNac level by Azaserin decreased the cardiac myofilaments sensi-
tivity to calcium pCa50 (p=0.05). This study highlights before clinical and
echocardiographic onset, an association between impaired contractile function,
an altered sensitivity to calcium, and a decreased O’GlcNacylation of possible
sarcomeric proteins in humans.
Abstract 0048 – Figure: Level of O’GlcNac of myofilaments proteins
0470
Role of Lipocalin 2 (LCN2) in cardiovascular remodeling induced by
aldosterone
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Neutrophil Gelatinase Associated Lipocalin or Lipocalin 2 (LCN2) is a
circulating protein, member of the lipocalin family, which binds MMP9
and modulates its stability and activity. We have recently shown that
LCN2 is a primary target of aldosterone/mineralocorticoid receptor (MR)
in endothelial cells, vascular smooth muscle cells and cardiomyocytes. We
hypothesized that LCN2 could be a mediator of aldosterone/MR profibro-
tic and proinflammatory effects in the cardiovascular system. Wild type
(WT) and LCN2 Knock Out (KO) mice were subjected to an uni-nephrec-
tomy aldosterone salt challenge (NAS, 200μg/kg/day of aldo, 1% NaCl in
tap water) for 4 weeks. Blood pressure (SBP) was measured by tail cuff
method. Cardiovascular fibrosis and inflammation were analyzed by RT-
PCR, western blot, immunohistochemistry and ELISA. There was no dif-
ference in SBP between transgenic mice compared to WT mice in basal
condition. With NAS challenge, SBP was increased only in WT mice
(SBP; CT 107±3, CT NAS 133±5, KO 109±3, KO NAS 115±3 mmHg).
Quantification of pro collagen I N-terminal peptide (PINP) in plasma
showed an increase of PINP due to NAS treatment in WT that was pre-
vented by LCN2 inactivation (CT 83±15, CT NAS 129±10, KO 70±19,
KO NAS 59±12 μg/l). In myocardium, NAS treatment increased collagen
type I and perivascular fibrosis in WT whereas KO were resistant to fibro-
sis (Collagen Volume Fraction; CT 19±3, CT NAS 28±2, KO 20±3, KO
NAS 20±3%). In aorta, collagen type I, vascular fibrosis and osteopontin
were also increased by NAS in WT. These increases were prevented by
LCN2 inactivation (CVF; CT 24±4, CT NAS 34±5, KO 21±2, KO NAS
28±2%). Our results show that LCN2 plays a key role in aldosterone/MR-
mediated vascular fibrosis and inflammation, but not in cardiac interstitial
fibrosis and vascular dysfunction. We are now analyzing 1) the specificity
of aldo/MR versus other pro-fibrotic challenges (AngII, catecholamines)
as well as 2) the role of inflammation in the effects mediated by Lcn2.
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Sympathetic overactivity: a very early manifestation of metabolic syn-
drome
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Sympathetic overactivity is a hallmark of metabolic syndrome (MS). Data
showing sympathetic overactivity in patients with early cardiovascular and
metabolic disorders, i.e., prodromal forms of MS, are lacking. Sympathetic
activity was measured by microneurography (MSNA), heart rate variability
(HRV), blood pressure variability (BPV) and plasma and urinary catechol-
amines. β2-adrenergic receptor (β2-AR) and the G-protein coupled receptor
kinase 2 (GRK2) mRNA expression levels were tested as possible markers of
sympathetic activity in blood mononuclear cells (PBMCs). 40 healthy volun-
teers and 16 patients with established (  3 components of the MS) and 23
incomplete (two components) MS were compared. MSNA was not only
increased in patients with overt MS but also among patients with incomplete
MS (P<0.001). In PBMCs of patients with incomplete MS, a significant 3.4
fold increase in the β2-AR over GRK2 mRNAs expression ratio was observed
(P=0.001); this ratio correlated well with MSNA. (Funded by the Clinical
Research program of the French Ministery of Health)
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Admission glycaemia: the crystal ball to assess prognosis value after
STEMI
Fatma Ben Amor, Majed Hassine, Ghassen Chniti, Marouen Mahjoub,
Nidhal Bouchahda, Zohra Dridi, Fethi Betbout, Habib Gamra
Hôpital Fattouma Bourguiba, Cardiologie A, Monastir, Tunisie
Introduction: High glycaemia at admission in STEMI patients is common
and associated with an increased risk of in-hospital and post-discharge death.
Aim: To evaluate the impact of admission glycaemia in the short prognosis
of diabetic and non-diabetic patients admitted for STEMI and to identify inde-
pendent predictors of post-ACS mortality.
Population and methods: This study included 567 patients admitted to a
single coronary care unit for STEMI, between January 2004 and June 2012.
Our population was divided in three groups according to the tertiles of gly-
caemia at admission (T1<7; T2=7-11 e T3>11 mmol/l). Rates of success after
revascularisation, intrahospital mortality, and ventricular arrhythmias were
collected
Results: Hyperglycaemia at admission was associated to worse cardiovas-
cular risk profile, more severe coronary disease (more 3 vessel disease),
incomplete revascularization, higher creatinine levels and more life threat-
ening ventricular arrhythmias (VT/VF). In the predefined tertiles, in-hospital
mortality was 4%, 5.2% and 14% (p<0.001). Life threatening arrhythmias
were respectively 2.4%; 4% and 9% (p:0.017). In the group of patients with
glycemia >11 mmol/l (224 patients), outcomes were similar between the dia-
betic and non diabetic patients with death rates respectively 13.8% and 13.9%
(p:0.988) In a multivariate analysis, predictive factors of intrahospital mor-
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